-
Mashup Score: 0
The final analysis of a phase 2 trial confirmed “substantial activity” and prolonged survival in treatment-naïve and previously treated patients with ALK-positive NSCLC, researchers wrote.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Phase 3 data revealed similar safety and efficacy outcomes with SCT510 and bevacizumab.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
The biosimilar SCT510 produces similar outcomes as its reference product, bevacizumab, in patients with non-small cell #lungcancer. Published in @AdvancesTherapy. https://t.co/5IltM2byVf #NSCLC #lcsm
-
-
Mashup Score: 0
Lazertinib staved off intracranial progression in patients with EGFR-mutant NSCLC who had received prior EGFR TKI treatment.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Lazertinib could be a treatment option for patients with EGFR-mutant non-small cell #lungcancer whose central nervous system metastases progressed after prior EGFR TKI treatment. From @JAMAOnc and @CancerTherAdvsr. https://t.co/Q4XhnE9vLC #NSCLC #lcsm
-
-
Mashup Score: 0Integrated Narrative Program Enhances Patient Resilience, NSCLC Outcomes - Oncology Nurse Advisor - 2 month(s) ago
Researchers conduct experimental trial to explore the effectiveness of combining 2 proven narrative therapies to improve resilience, self-efficacy, and QOL in patients with NSCLC.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
An integrated narrative program was more effective at improving QOL in patients who have undergone surgical treatment of non-small cell #lungcancer than a digital storytelling intervention. https://t.co/y38EPuIDT3 #NSCLC #lcsm
-
-
Mashup Score: 6Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations - 2 month(s) ago
Germline mutations driving lung cancer have been infrequently reported in the literature, with EGFR T790M being a known germline mutation identified in 1% of NSCLCs. Typically, a somatic EGFR mutation is acquired to develop lung adenocarcinoma. Osimertinib has become a standard-of-care treatment for EGFR T790M-positive lung cancer.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
In this retrospective analysis through the #LungCancer Moon Shot GEMINI database @ the @MDAndersonNews Xiuning Le et al. found that osimertinib for advanced germline EGFR-mutated #NSCLC renders similar PFS compared to somatic T790M EGFR-mutated NSCLC.https://t.co/saMQYqSivW #LCSM https://t.co/AyW6pbr2u5
-
-
Mashup Score: 0
SBRT and hypofractionated CRT produced similar outcomes in patients with inoperable stage I NSCLC in a phase 3 trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Stereotactic body radiotherapy and hypofractionated conventional radiotherapy are equally effective for inoperable stage I non-small cell #lungcancer. Published in @JAMAOnc. https://t.co/DGWEM5E7d1 #NSCLC #LCSM
-
-
Mashup Score: 1Data Support IMRT as Standard Care for Locally Advanced NSCLC - 3 month(s) ago
Use of IMRT should be standard for patients with unresectable, locally advanced NSCLC receiving chemoradiation, according to researchers.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Use of IMRT should be standard for patients with unresectable, locally advanced non-small cell #lungcancer receiving chemoradiation, according to researchers. From @JAMAOnc. https://t.co/oPGb3tS1u8 #NSCLC #LCSM
-
-
Mashup Score: 1
Lifileucel produced responses in patients with previously treated, advanced non-small cell lung cancer in a phase 2 trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Lifileucel can produce responses in patients with previously treated, advanced non-small cell #lungcancer. Published in @CD_AACR. https://t.co/mkMMvAYdIB #NSCLC #LCSM
-
-
Mashup Score: 0Vebreltinib Proves Active in Advanced METex14-Mutant NSCLC - Oncology Nurse Advisor - 4 month(s) ago
The c-MET inhibitor vebreltinib has demonstrated “promising efficacy” in patients with advanced non-small cell lung cancer and MET exon 14 skipping mutations, according to researchers.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Oncologists1Tweet-
The c-MET inhibitor vebreltinib produced durable responses in patients with advanced non-small cell #lungCancer and METex14 mutations. Published in @JCO_ASCO. https://t.co/KYhrPozceV #NSCLC #LCSM
-
-
Mashup Score: 0
Having a BRAF mutation is associated with improved outcomes of immunotherapy-based treatment in patients with locally advanced or metastatic NSCLC.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Having a BRAF mutation is associated with improved outcomes of immunotherapy-based treatment in patients with locally advanced or metastatic non-small cell #lungcancer. From @LungCaJournal. https://t.co/Lo2y2VIgWq #NSCLC #LCSM
-
Lorlatinib demonstrated “substantial activity” in patients with treatment-naïve and previously treated non-small cell #lungcancer in a phase 2 trial, according to researchers. Reported in @JTOonline. https://t.co/HuNWWco5O9 #NSCLC #lcsm